Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum Sensitive Ovarian Cancer Patients

Status: Recruiting
Phase: Phase 2
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer
NCT ID: NCT01611558 (View complete trial on
DFCI Protocol ID: 12-292


To assess the incidence of drug-related adverse events of Grade 3 or higher during the induction period of Ipilimumab.


Conducting Institutions:
Beth-Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital

Overall PI:
Ursula Matulonis, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Panagiotis Konstantinopoulos, MD, Dana-Farber Cancer Institute
Michael Birrer, MD, PhD, Massachusetts General Hospital

Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060
Dana-Farber Cancer Institute: Christin Whalen, 617-582-7738,
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Recurrent Platinum Sensitive - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Exclusion Criteria: - Platinum Refractory ovarian cancer - More than 4 lines of prior therapy
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms